HEALTHMEDPAGE TODAY
New Drug Prevents Worsening Pulmonary Arterial Hypertension in Major Trial Win
Oral ralinepag may receive FDA approval after showing effectiveness in preventing worsening of pulmonary arterial hypertension in a phase III trial. The drug's success in the ADVANCE OUTCOMES trial could lead to its approval as a treatment for PAH.
Mentioned
Related Signal
Adjacent reporting
- What is pulmonary hypertension and why would a new GLP-1 help?
- STAT+: AstraZeneca picks up FDA approval for hypertension drug
- Scientists reveal new blood pressure treatment that works when others fail
- Drug slashes risk of developing rheumatoid arthritis by 60 percent, study suggests
- FDA approves a first-of-its-kind pill to cut cholesterol in high-risk patients